Search results
Results from the WOW.Com Content Network
Osteogenesis imperfecta is a group of genetic disorders, all of which cause bone fragility. OI has high genetic heterogeneity , that is, many different genetic mutations lead to the same or similar sets of observable symptoms ( phenotypes ).
Osteogenesis imperfecta, congenital dwarfisms, skeletal dysplasias: Treatment: Asfotase alfa (Strensiq), an enzyme replacement therapy: Prognosis: Severe perinatal forms are lethal without treatment; adult forms may only show moderate symptoms: Frequency: Rare (1 in 100,000); [3] more common in some populations [4]
It provides extensive evaluation and treatment programs for children and adults with various metabolic bone diseases including osteoporosis, osteomalacia, stress fractures in young athletic women and men, and minimum trauma and nontraumatic fractures in infants, children and adults with hypermobility syndromes, Osteogenesis imperfecta, and ...
In classic non-deforming osteogenesis imperfecta with blue sclerae or common variable osteogenesis imperfecta with normal sclerae, nearly 60% of cases are de novo. COL1A1/2-related osteogenesis imperfecta is identified by repeated fractures with trivial trauma, defective dentinogenesis imperfecta (DI), and hearing loss.
A bone fracture may be the result of high force impact or stress, or a minimal trauma injury as a result of certain medical conditions that weaken the bones, such as osteoporosis, osteopenia, bone cancer, or osteogenesis imperfecta, where the fracture is then properly termed a pathologic fracture. [3]
Treatment: Good diet, ... Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. ... These include osteogenesis imperfecta, ...
A pathologic fracture is a bone fracture caused by weakness of the bone structure that leads to decrease mechanical resistance to normal mechanical loads. [1] This process is most commonly due to osteoporosis, but may also be due to other pathologies such as cancer, infection (such as osteomyelitis), inherited bone disorders, or a bone cyst.
Zoledronic acid is indicated for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia) in people with advanced malignancies involving bone; the treatment of adults with tumor-induced hypercalcemia (TIH).